United Therapeutics (UTHR)

Executive Summary

United Therapeutics is a biotechnology leader focused on pulmonary arterial hypertension (PAH) and regenerative medicine, with approved therapies including Remodulin, Tyvaso, and Orenitram providing a strong commercial foundation. The company is expanding into oncology with novel assets like DT2216, a BCL-XL degrader being evaluated in platinum-resistant ovarian cancer, and dinutuximab combination therapy for neuroblastoma. Beyond oncology, United Therapeutics is pioneering xenotransplantation, aiming to address the organ shortage with gene-edited pig organs. With a robust pipeline and diversified revenue streams, the company is positioned for sustained growth, though late-stage pipeline concentration and regulatory risks remain key considerations.

Upcoming Catalysts (preview)

• H2 2026Phase 1 data readout for DT2216 in platinum-resistant ovarian cancer60% success
• H1 2026Phase 1 completion and data for dinutuximab + chemotherapy in neuroblastoma70% success
• 2026Regulatory update on xenotransplantation clinical trials (e.g., FDA/UK approval for pig kidney transplant studies)50% success